

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Malin Life Sciences Holdings Ltd</u> (Last) (First) (Middle) THE LENNOX BUILDING 50 RICHMOND STREET SOUTH (Street) DUBLIN L2 D02 FK02 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 07/09/2020	3. Issuer Name and Ticker or Trading Symbol <u>Poseida Therapeutics, Inc. [PSTX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Convertible Preferred Stock	(1)	(1)	Common Stock	7,013,918	(1)	D ⁽²⁾	
Series A-1 Convertible Preferred Stock	(1)	(1)	Common Stock	1,168,985	(1)	D ⁽²⁾	
Series B Convertible Preferred Stock	(1)	(1)	Common Stock	690,124	(1)	D ⁽²⁾	
Series C Convertible Preferred Stock	(1)	(1)	Common Stock	315,098	(1)	D ⁽²⁾	

1. Name and Address of Reporting Person*
Malin Life Sciences Holdings Ltd

 (Last) (First) (Middle)
 THE LENNOX BUILDING
 50 RICHMOND STREET SOUTH

 (Street)
 DUBLIN L2 D02 FK02

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
Malin Corp plc

 (Last) (First) (Middle)
 THE LENNOX BUILDING

50 RICHMOND STREET SOUTH

(Street)

DUBLIN

L2

D02 FK02

(City)

(State)

(Zip)

Explanation of Responses:

1. All shares of preferred stock, \$0.0001 par value per share, of the Issuer, (i) are reflective of a 1-for-1.247 reverse stock split on the Issuer's common stock, \$0.0001 par value per share ("Common Stock"), which became effective on July 2, 2020, (ii) have no expiration date and (iii) will automatically convert into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.

2. Malin Life Sciences Holdings Ltd, the record holder of the shares, is a wholly owned subsidiary of Malin Corporation plc. Malin Corporation plc may be deemed to beneficially own the shares and may be deemed to share voting and dispositive power over these shares.

Remarks:

(1) Exhibit 24 - Power of Attorney (2) Exhibit 99.1 - Joint Filer Information

Malin Life Sciences

Holdings Ltd, By: /s/

Michael A. Goldstein,

Esq., Attorney-in-Fact

07/09/2020

Malin Corporation plc, By:

/s/ Michael A. Goldstein,

Esq., Attorney-in-Fact

07/09/2020

** Signature of Reporting

Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

**MALIN LIFE SCIENCES HOLDINGS LTD AND MALIN CORPORATION PLC (together, the “Filer”)
LIMITED POWER OF ATTORNEY**

KNOW ALL BY THESE PRESENTS, that each of the undersigned hereby constitutes and appoints Pat Jennings, Michael Goldstein and Brian Tribuna, subject to the expiration of this Limited Power of Attorney as set forth below, and each of them signing singly, and with full power of substitution, as the undersigned’s true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, and submit to the U.S. Securities and Exchange Commission (the “SEC”) a Form ID and the Form ID Confirming Statement, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings of a Forms 3, 4, and 5 with the SEC required by Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) for the undersigned;
- (2) execute for and on behalf of the undersigned Forms 3, 4, and 5 in accordance with Section 16(a) of the Exchange Act, and the rules thereunder;
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is Poseida Therapeutics, Inc., a Delaware corporation (the “Company”), assuming, any responsibilities of the undersigned to comply with Section 16(a) of the Exchange Act, or any other law, rule or regulation whatsoever.

This Limited Power of Attorney shall remain in full force and effect until the earlier of (i) the time that the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, and (iii) the revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned have caused this Limited Power of Attorney to be executed as of July 8, 2020.

Malin Life Sciences Holdings Ltd

By: /s/ Fiona Dunlevy

Name: Fiona Dunlevy

Malin Corporation plc

By: /s/ Darragh Lyons

Name: Darragh Lyons

FORM 3 JOINT FILER INFORMATION

Names of Joint Filers:

Malin Life Sciences Holdings Ltd
Malin Corporation plc

Address of Joint Filers:

The Lennox Building
50 Richmond Street South
Dublin
D02 FK02
Ireland

Designated Filer:

Malin Life Sciences Holdings Ltd

Issuer and Ticker Symbol:

Poseida Therapeutics, Inc. [PSTX]

Date of Event:

July 9, 2020

Signatures of Joint Filers:

Malin Life Sciences Holdings Ltd

By: /s/ Michael A. Goldstein, Esq.
Attorney-in-Fact

Malin Corporation plc

By: /s/ Michael A. Goldstein, Esq.
Attorney-in-Fact
